Techniques for advanced glycation end product measurements for diabetic bone disease: pitfalls and future directions.
Journal
Current opinion in endocrinology, diabetes, and obesity
ISSN: 1752-2978
Titre abrégé: Curr Opin Endocrinol Diabetes Obes
Pays: England
ID NLM: 101308636
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
2
7
2022
medline:
12
7
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
Multiple biochemical and biophysical approaches have been broadly used for detection and quantitation of posttranslational protein modifications associated with diabetic bone, yet these techniques present a variety of challenges. In this review, we discuss recent advancements and complementary roles of analytical (UPLC/UPLC-MS/MS and ELISA) and biophysical (Raman and FTIR) techniques used for characterization of glycation products, measured from bone matrix and serum, and provide recommendations regarding the selection of a technique for specific study of diabetic bone. Hyperglycemia and oxidative stress in diabetes contribute to the formation of a large subgroup of advanced glycation end products (AGEs) known as glycoxidation end products (AGOEs). AGEs/AGOEs have various adverse effects on bone health. Commonly, accumulation of AGEs/AGOEs leads to increased bone fragility. For example, recent studies show that carboxymethyllysine (CML) and pentosidine (PEN) are formed in bone at higher levels in certain diseases and metabolic conditions, in particular, in diabetes and aging. Detection and quantitation of AGEs/AGOEs in rare and/or precious samples is feasible because of a number of technological advancements of the past decade. Recent technological advancements have led to a significant improvement of several key analytical biochemistry and biophysics techniques used for detection and characterization of AGEs/AGOEs in bone and serum. Their principles and applications to skeletal tissue studies as well as limitations are discussed in this review.
Identifiants
pubmed: 35777968
doi: 10.1097/MED.0000000000000736
pii: 01266029-202208000-00006
pmc: PMC9348815
mid: NIHMS1811750
doi:
Substances chimiques
Glycation End Products, Advanced
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-342Subventions
Organisme : NIA NIH HHS
ID : R01 AG020618
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG063063
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG020618
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130:456–469.
Guntur AR, Rosen CJ. Bone as an endocrine organ. Endocr Pract 2012; 18:758–762.
Ferron M, Lacombe J. Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch Biochem Biophys 2014; 561:137–146.
Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone 2016; 82:42–49.
Ng KW. Regulation of glucose metabolism and the skeleton. Clin Endocrinol (Oxf) 2011; 75:147–155.
Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94:2380–2386.
Lamb LS, Alfonso H, Norman PE, et al. Advanced glycation end products and esRAGE are associated with bone turnover and incidence of hip fracture in older men. J Clin Endocrinol Metab 2018; 103:4224–4231.
Yamamoto M, Sugimoto T. Advanced glycation end products, diabetes, and bone strength. Curr Osteoporos Rep 2016; 14:320–326.
Piccoli A, Cannata F, Strollo R, et al. Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes. J Bone Miner Res 2020; 35:2415–2422.
Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5:194–222.
Burgos-Morón E, Abad-Jiménez Z, Marañón AM, et al. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: the battle continues. J Clin Med 2019; 8:E1385.
Moldogazieva NT, Mokhosoev IM, Mel’nikova TI, et al. Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGEs) in aging and age-related diseases. Oxid Med Cell Longev 2019; 2019:3085756.
Sroga GE, Vashishth D. Controlled formation of carboxymethyllysine in bone matrix through designed glycation reaction. JBMR Plus 2021; 5:e10548.
Tice MJL, Bailey S, Sroga GE, et al. Non-obese MKR mouse model of type 2 diabetes reveals skeletal alterations in mineralization and material properties. JBMR Plus 2022; 6:e10583.
LLabre JE, Sroga GE, Tice MJL, Vashishth D. Induction and rescue of skeletal fragility in a high-fat diet mouse model of type 2 diabetes: an in vivo and in vitro approach. Bone 2022; 156:116302.
Sanguineti R, Puddu A, Mach F, et al. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm 2014; 2014:975872.
Chaudhuri J, Bains Y, Guha S, et al. The role of advanced glycation end products in aging and metabolic diseases: bridging association and causality. Cell Metab 2018; 28:337–352.
Vistoli G, De Maddis D, Cipak A, et al. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013; 47: (Suppl 1): 3–27.
Thomas CJ, Cleland TP, Sroga GE, Vashishth D. Accumulation of carboxymethyl-lysine (CML) in human cortical bone. Bone 2018; 110:128–133.
Tang SY, Vashishth D. Nonenzymatic glycation alters microdamage formation in human cancellous bone. Bone 2010; 46:148–154.
Diab T, Condon KW, Burr DB, Vashishth D. Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone 2006; 38:427–431.
Domazetovic V, Marcucci G, Iantomasi T, et al. Oxidative stress in bone remodeling: role of antioxidants. Clin Cases Miner Bone Metab 2017; 14:209–216.
Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001; 28:195–201.
Tang SY, Zeenath U, Vashishth D. Effects of nonenzymatic glycation on cancellous bone fragility. Bone 2007; 40:1144–1151.
Sroga GE, Siddula A, Vashishth D. Glycation of human cortical and cancellous bone captures differences in the formation of Maillard reaction products between glucose and ribose. PLoS One 2015; 10:e0117240.
Sroga GE, Vashishth D. Phosphorylation of extracellular bone matrix proteins and its contribution to bone fragility. J Bone Miner Res 2018; 33:2214–2229.
Bradke BS, Vashishth D. N-phenacylthiazolium bromide reduces bone fragility induced by nonenzymatic glycation. PLoS One 2014; 9:e103199.
Taleuzzaman M, Ali S, Gilani SJ, et al. Ultra-performance liquid chromatography (UPLC) - a review. J Anal Pharm Chem 2015; 2:1056.
Walter TH, Andrews RW. Recent innovations in UHPLC columns and instrumentation. TrAC Trends Anal Chem 2014; 63:14–20.
Singh S, Prasad L, Kumar V, et al. Ultra performance liquid chromatography: high throughput analysis over high performance liquid chromatography. Int J Eng Allied Sci 2016; 2:19–25.
Basharat R, Kotra V, Loong LY, et al. A mini-review on ultra performance liquid chromatography. Orient J Chem 2021; 37:847–857.
Sroga GE, Vashishth D. UPLC methodology for identification and quantitation of naturally fluorescent crosslinks in proteins: a study of bone collagen. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:379–385.
Sroga GE, Karim L, Colón W, Vashishth D. Biochemical characterization of major bone-matrix proteins using nanoscale-size bone samples and proteomics methodology. Mol Cell Proteomics 2011; 10:M110.006718.
Sroga GE, Wu P-C, Vashishth D. Insulin-like growth factor 1, glycation and bone fragility: implications for fracture resistance of bone. PLoS One 2015; 10:e0117046.
Mulani FA, Nandikol SS, Haldar S, Thulasiram HV. Accurate identification of bioactive meliaceae limonoids by UHPLC–MS/MS based structure–fragment relationships (SFRs). ACS Omega 2021; 6:26454–26476.
Bian Y, Zheng R, Bayer FP, et al. Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC–MS/MS. Nat Commun 2020; 11:157.
Kawashima Y, Ohara O. Development of a NanoLC–MS/MS system using a nonporous reverse phase column for ultrasensitive proteome analysis. Anal Chem 2018; 90:12334–12338.
Soboleva A, Vikhnina M, Grishina T, Frolov A. Probing protein glycation by chromatography and mass spectrometry: analysis of glycation adducts. Int J Mol Sci 2017; 18:E2557.
Arakawa S, Suzuki R, Kurosaka D, et al. Mass spectrometric quantitation of AGEs and enzymatic crosslinks in human cancellous bone. Sci Rep 2020; 10:18774.
van Huizen NA, Ijzermans JNM, Burgers PC, Luider TM. Collagen analysis with mass spectrometry. Mass Spectrom Rev 2020; 39:309–335.
Rabbani N, Ashour A, Thornalley PJ. Mass spectrometric determination of early and advanced glycation in biology. Glycoconj J 2016; 33:553–568.
Hudson DM, Archer M, King KB, Eyre DR. Glycation of type I collagen selectively targets the same helical domain lysine sites as lysyl oxidase-mediated cross-linking. J Biol Chem 2018; 293:15620–15627.
Thomas CJ, Cleland TP, Zhang S, et al. Identification and characterization of glycation adducts on osteocalcin. Anal Biochem 2017; 525:46–53.
Karsenty G. Update on the biology of osteocalcin. Endocr Pract 2017; 23:1270–1274.
Moser SC, van der Eerden BCJ. Osteocalcin—a versatile bone-derived hormone. Front Endocrinol (Lausanne) 2019; 9:794.
Nikel O, Poundarik AA, Bailey S, Vashishth D. Structural role of osteocalcin and osteopontin in energy dissipation in bone. J Biomech 2018; 80:45–52.
Poundarik AA, Boskey A, Gundberg C, Vashishth D. Biomolecular regulation, composition and nanoarchitecture of bone mineral. Sci Rep 2018; 8:1191.
Poundarik AA, Diab T, Sroga GE, et al. Dilatational band formation in bone. PNAS 2012; 109:19178–19183.
Poundarik A, Karim L, Gundberg C, Vashishth D. The role of osteocalcin in bone fracture. In: 55th Annual Meeting of the Orthopaedic Research Society, Las Vegas, NV, 22–25 February 2009 [poster 724].
Rodrigues AM, Caetano-Lopes J, Vale AC, et al. Low osteocalcin/collagen type I bone gene expression ratio is associated with hip fragility fractures. Bone 2012; 51:981–989.
Bronowicka-Szydełko A, Krzystek-Korpacka M, Gacka M, et al. Association of novel advanced glycation end-product (AGE10) with complications of diabetes as measured by enzyme-linked immunosorbent assay. J Clin Med 2021; 10:4499.
Human elisa kits - MyBioSource [Internet]. [cited 2 March 2022]. Available at: https://www.mybiosource.com/human-elisa-kits/CML-AGE/263691 . [Accessed 6 June 2022]
Pentosidine elisa kit | Human Pentosidine ELISA Kit [Internet]. [cited 2 March 2022]. Available at: https://www.mybiosource.com/human-elisa-kits/pentosidine/704095 . [Accessed 6 June 2022]
Haddad M, Knani I, Bouzidi H, et al. Plasma levels of pentosidine, carboxymethyl-lysine, soluble receptor for advanced glycation end products, and metabolic syndrome: the metformin effect. Dis Markers 2016; 2016:6248264.
Barzilay JI, Bůžková P, Zieman SJ, et al. Circulating levels of carboxy-methyl-lysine (CML) are associated with hip fracture risk: the Cardiovascular Health Study. J Bone Miner Res 2014; 29:1061–1066.
Dhaliwal R, Ewing SK, Vashishth D, et al. Greater carboxy-methyl-lysine is associated with increased fracture risk in type 2 diabetes. J Bone Miner Res 2022; 37:265–272.
Sihota P, Yadav RN, Dhaliwal R, et al. Investigation of mechanical, material, and compositional determinants of human trabecular bone quality in type 2 diabetes. J Clin Endocrinol Metab 2021; 106:e2271–e2289.
Karim L, Vashishth D. Heterogeneous glycation of cancellous bone and its association with bone quality and fragility. PLoS One 2012; 7:e35047.
Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006; 79:160–168.
Shiraki M, Kuroda T, Tanaka S, et al. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 2008; 26:93–100.
Taylor EA, Donnelly E. Raman and Fourier transform infrared imaging for characterization of bone material properties. Bone 2020; 139:115490.
Yeni YN, Yerramshetty J, Akkus O, et al. Effect of fixation and embedding on Raman spectroscopic analysis of bone tissue. Calcif Tissue Int 2006; 78:363–371.
Gamsjaeger S, Srivastava AK, Wergedal JE, et al. Altered bone material properties in HLA-B27 rats include reduced mineral to matrix ratio and altered collagen cross-links. J Bone Miner Res 2014; 29:2382–2391.
Rubin MR, Paschalis EP, Poundarik A, et al. Advanced glycation endproducts and bone material properties in type 1 diabetic mice. PLoS One 2016; 11:e0154700.
Unal M, Uppuganti S, Leverant CJ, et al. Assessing glycation-mediated changes in human cortical bone with Raman spectroscopy. J Biophotonics 2018; 11:e201700352.
Colsoul N, Marin C, Corbeels K, et al. Alteration of the condylar oral bone in obese and gastric bypass mice. Calcif Tissue Int 2020; 107:371–380.
Marin C, Papantonakis G, Sels K, et al. Unraveling the compromised biomechanical performance of type 2 diabetes- and Roux-en-Y gastric bypass bone by linking mechanical-structural and physico-chemical properties. Sci Rep 2018; 8:5881.
Sharma B, Ma K, Glucksberg MR, Van Duyne RP. Seeing through bone with surface-enhanced spatially offset raman spectroscopy. J Am Chem Soc 2013; 135:17290–17293.
Taylor EA, Lloyd AA, Salazar-Lara C, Donnelly E. Raman and fourier transform infrared (FT-IR) mineral to matrix ratios correlate with physical chemical properties of model compounds and native bone tissue. Appl Spectrosc 2017; 71:2404–2410.
Hunt HB, Pearl JC, Diaz DR, et al. Bone tissue collagen maturity and mineral content increase with sustained hyperglycemia in the KK-Ay murine model of type 2 diabetes. J Bone Miner Res 2018; 33:921–929.
Schmidt FN, Zimmermann EA, Campbell GM, et al. Assessment of collagen quality associated with nonenzymatic cross-links in human bone using Fourier-transform infrared imaging. Bone 2017; 97:243–251.
Sihota P, Yadav RN, Poleboina S, et al. Development of HFD-fed/low-dose STZ-treated female Sprague-Dawley rat model to investigate diabetic bone fragility at different organization levels. JBMR Plus 2020; 4:e10379.